At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Mar 30, 2026 at 07:15 ET
Royalty Pharma announced a $500 million R&D co-funding agreement with Johnson & Johnson to advance JNJ-4804, an investigational dual-pathway inhibitor for autoimmune diseases. The deal reflects Royalty Pharma's strategy of funding late-stage innovation in immunology, but carries development-stage risk with no near-term revenue impact. This is a non-dilutive use of capital that could yield future royalty streams if the therapy succeeds.
- Royalty Pharma and Johnson & Johnson entered a $500 million co-funding agreement for JNJ-4804 development in 2026–2027
- JNJ-4804 is a novel co-antibody therapy targeting IL-23 and TNF pathways for chronic immune-mediated diseases
- The collaboration builds on Royalty Pharma's immunology investment strategy and existing royalty relationship with J&J (Tremfya)
- No equity exchange or ownership stake mentioned, structured as a development funding partnership
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access